Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 October 2019Website:
http://www.korrobio.comNext earnings report:
26 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 80 min agoDividend
Analysts recommendations
Institutional Ownership
KRRO Latest News
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110
The consensus price target hints at a 239.5% upside potential for Korro Bio, Inc. (KRRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024.
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2024 and provided an update on its recent progress and anticipated milestones.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
The average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What type of business is Korro Bio?
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
What sector is Korro Bio in?
Korro Bio is in the Healthcare sector
What industry is Korro Bio in?
Korro Bio is in the Biotechnology industry
What country is Korro Bio from?
Korro Bio is headquartered in United States
When did Korro Bio go public?
Korro Bio initial public offering (IPO) was on 03 October 2019
What is Korro Bio website?
https://www.korrobio.com
Is Korro Bio in the S&P 500?
No, Korro Bio is not included in the S&P 500 index
Is Korro Bio in the NASDAQ 100?
No, Korro Bio is not included in the NASDAQ 100 index
Is Korro Bio in the Dow Jones?
No, Korro Bio is not included in the Dow Jones index
When was Korro Bio the previous earnings report?
No data
When does Korro Bio earnings report?
The next expected earnings date for Korro Bio is 26 February 2025